Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | ATG-101 |
Trade Name | |
Synonyms | ATG101|ATG 101 |
Drug Descriptions |
ATG-101 is a tetravalent bispecific antibody targeting PD-L1 (CD274) and TNFRSF9 (4-1BB), which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 TNFRSF9 Antibody 30 |
CAS Registry Number | NA |
NCIT ID | C190124 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ATG-101 | ATG-101 | 0 | 1 |